Table 2.

Treatment-Emergent AEs in ACTIVExtend, Cumulative Mo 19 to 43

Summary of TEAEs, ACTIVExtend Safety Population (N = 1133)	PBO/ALN (n = 580), n (%)	ABL/ALN (n = 553), n (%)
≥1 TEAE	466 (80.3)	452 (81.7)
≥1 Severe TEAE	40 (6.9)	38 (6.9)
≥1 Serious TEAE	58 (10.0)	65 (11.8)
≥1 TEAE leading to death	2 (0.3)	0
≥1 TEAE leading to discontinuation	36 (6.2)	30 (5.4)
Most frequently (≥5% in either group) reported TEAEs
Arthralgia	58 (10.0)	54 (9.8)
Upper respiratory tract infection	51 (8.8)	40 (7.2)
Back pain	34 (5.9)	36 (6.5)
Hypertension	33 (5.7)	27 (4.9)
Pain in extremity	31 (5.3)	23 (4.2)
Osteoarthritis	21 (3.6)	28 (5.1)